繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-630

SNP-630

Indication
Non-alcoholic steatohepatitis (NASH)
Product Advantages
1. Optimized New Chemical Entity
2. First-in-class
3. For NASH and ASH
Status
1. Pre-clinical
2. SNP-630 and/or its active metabolites: some human experience
3. Plan to apply US FDA IND, fast track and breakthrough designation
Competitive Edge
1. Multiple mechanisms of action
2. Direct action on liver
3. Optimal potency
4. Great safety profile
Potential Market
The estimated global market for NASH: 35-40 B per year

Multiple Mechanisms of Action of SNP-6xx


体彩p5中奖新闻 浙江十一选五 上海时时乐开奖视屏 北京快乐8开奖app 安徽11选5开奖一定牛 青海快3开奖结果昨天 广东快乐十分公告 多乐彩11选5开奖结果 快乐十分钟开奖号码 山东11选五预测号码推荐 华谊兄弟股票分析报告